ID

43824

Description

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01288092

Link

https://clinicaltrials.gov/show/NCT01288092

Keywords

Versions (2)
  1. 3/13/16 3/13/16 -
  2. 9/20/21 9/20/21 -
Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Metastatic Breast Cancer NCT01288092

English

Eligibility Metastatic Breast Cancer NCT01288092

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
female ≥ 18 years
Description

female; age

Data type

boolean

Alias
UMLS CUI [1]
C0086287
UMLS CUI [2]
C0001779
ecog performance status ≤ 2
Description

ecog performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
histologically and/or cytologically confirmed diagnosis of breast cancer presenting with metastatic disease (hormone receptor positive and her2 negative)
Description

Neoplasm Metastasis breast cancer; Hormone receptor positive tumor; her2 negative breast cancer

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0006142
UMLS CUI [2]
C1563119
UMLS CUI [3]
C2316304
known pi3k activation status (defined by pik3ca (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutation and pten pten (phosphatase and tensin homolog) mutation/expression)
Description

phosphoinositide-3-kinase, catalytic alpha; mutation PTEN gene

Data type

boolean

Alias
UMLS CUI [1]
C1310696
UMLS CUI [2,1]
C0026882
UMLS CUI [2,2]
C0694888
prior treatment with at least one prior line of endocrine therapy and at least two and no more than three prior lines of chemotherapy for metastatic breast cancer
Description

endocrine therapy; chemotherapy metastatic breast cancer

Data type

boolean

Alias
UMLS CUI [1]
C0279025
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0278488
objective and radiologically confirmed progression of disease after prior treatment and at least one measurable lesion as per recist
Description

Measurable Disease; Cancer Progression

Data type

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1947901
adequate bone marrow and organ function
Description

organ function; bone marrow function

Data type

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2]
C0412480
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment with pi3k and/or mtor inhibitors
Description

mtor inhibitors; phosphoinositide-3-kinase

Data type

boolean

Alias
UMLS CUI [1]
C1515672
UMLS CUI [2]
C1310696
symptomatic central nervous system (cns) metastases
Description

cns metastase

Data type

boolean

Alias
UMLS CUI [1]
C0686377
concurrent malignancy or malignancy in the last 5 years prior to start of study treatment
Description

malignancy

Data type

boolean

Alias
UMLS CUI [1]
C0006826
wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study drug
Description

field radiotherapy; palliation radiation

Data type

boolean

Alias
UMLS CUI [1]
C3826993
UMLS CUI [2]
C0475092
active cardiac disease (e.g. left ventricular ejection fraction (lvef) < 50%, qtcf > 480 msec on screening ecgelectrocardiogram (ecg), unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)
Description

left ventricular ejection fraction; qtcf; electrocardiogram; Angina, Unstable; Cardiac Arrhythmia

Data type

boolean

Alias
UMLS CUI [1]
C0428772
UMLS CUI [2]
C1882513
UMLS CUI [3]
C0013798
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0003811
inadequately controlled hypertension
Description

hypertension

Data type

boolean

Alias
UMLS CUI [1]
C0020538
impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of bez235
Description

gastrointestinal disease; absorption bez235

Data type

boolean

Alias
UMLS CUI [1]
C0017178
UMLS CUI [2,1]
C2698776
UMLS CUI [2,2]
C2347425
treatment at start of study treatment with drugs with a known risk to induce torsades de pointes, moderate and strong inhibitors or inducers of isoenzyme cyp3a4, warfarin and coumadin analogues, lhrh agonists
Description

torsades de pointes; cyp3a4 inhibitor; warfarin; coumadin

Data type

boolean

Alias
UMLS CUI [1]
C0040479
UMLS CUI [2]
C3830624
UMLS CUI [3]
C0043031
UMLS CUI [4]
C0699129
history of photosensitivity reactions to other drugs
Description

drug photosensitivity

Data type

boolean

Alias
UMLS CUI [1]
C0263586
pregnant or nursing (lactating) woman
Description

pregnancy; lactating

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
other protocol-defined inclusion/exclusion criteria may apply
Description

exclusion criteria

Data type

boolean

Alias
UMLS CUI [1]
C0680251
Back to the top of the page

Similar models

Eligibility Metastatic Breast Cancer NCT01288092

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
female; age
Item
female ≥ 18 years
boolean
C0086287 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
ecog performance status
Item
ecog performance status ≤ 2
boolean
C1520224 (UMLS CUI [1])
Neoplasm Metastasis breast cancer; Hormone receptor positive tumor; her2 negative breast cancer
Item
histologically and/or cytologically confirmed diagnosis of breast cancer presenting with metastatic disease (hormone receptor positive and her2 negative)
boolean
C0027627 (UMLS CUI [1,1])
C0006142 (UMLS CUI [1,2])
C1563119 (UMLS CUI [2])
C2316304 (UMLS CUI [3])
phosphoinositide-3-kinase, catalytic alpha; mutation PTEN gene
Item
known pi3k activation status (defined by pik3ca (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutation and pten pten (phosphatase and tensin homolog) mutation/expression)
boolean
C1310696 (UMLS CUI [1])
C0026882 (UMLS CUI [2,1])
C0694888 (UMLS CUI [2,2])
endocrine therapy; chemotherapy metastatic breast cancer
Item
prior treatment with at least one prior line of endocrine therapy and at least two and no more than three prior lines of chemotherapy for metastatic breast cancer
boolean
C0279025 (UMLS CUI [1])
C0392920 (UMLS CUI [2,1])
C0278488 (UMLS CUI [2,2])
Measurable Disease; Cancer Progression
Item
objective and radiologically confirmed progression of disease after prior treatment and at least one measurable lesion as per recist
boolean
C1513041 (UMLS CUI [1])
C1947901 (UMLS CUI [2])
organ function; bone marrow function
Item
adequate bone marrow and organ function
boolean
C0678852 (UMLS CUI [1])
C0412480 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
mtor inhibitors; phosphoinositide-3-kinase
Item
previous treatment with pi3k and/or mtor inhibitors
boolean
C1515672 (UMLS CUI [1])
C1310696 (UMLS CUI [2])
cns metastase
Item
symptomatic central nervous system (cns) metastases
boolean
C0686377 (UMLS CUI [1])
malignancy
Item
concurrent malignancy or malignancy in the last 5 years prior to start of study treatment
boolean
C0006826 (UMLS CUI [1])
field radiotherapy; palliation radiation
Item
wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study drug
boolean
C3826993 (UMLS CUI [1])
C0475092 (UMLS CUI [2])
left ventricular ejection fraction; qtcf; electrocardiogram; Angina, Unstable; Cardiac Arrhythmia
Item
active cardiac disease (e.g. left ventricular ejection fraction (lvef) < 50%, qtcf > 480 msec on screening ecgelectrocardiogram (ecg), unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)
boolean
C0428772 (UMLS CUI [1])
C1882513 (UMLS CUI [2])
C0013798 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0003811 (UMLS CUI [5])
hypertension
Item
inadequately controlled hypertension
boolean
C0020538 (UMLS CUI [1])
gastrointestinal disease; absorption bez235
Item
impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of bez235
boolean
C0017178 (UMLS CUI [1])
C2698776 (UMLS CUI [2,1])
C2347425 (UMLS CUI [2,2])
torsades de pointes; cyp3a4 inhibitor; warfarin; coumadin
Item
treatment at start of study treatment with drugs with a known risk to induce torsades de pointes, moderate and strong inhibitors or inducers of isoenzyme cyp3a4, warfarin and coumadin analogues, lhrh agonists
boolean
C0040479 (UMLS CUI [1])
C3830624 (UMLS CUI [2])
C0043031 (UMLS CUI [3])
C0699129 (UMLS CUI [4])
drug photosensitivity
Item
history of photosensitivity reactions to other drugs
boolean
C0263586 (UMLS CUI [1])
pregnancy; lactating
Item
pregnant or nursing (lactating) woman
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
exclusion criteria
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C0680251 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial